Overall verdict
Buy
6.8/10
1-year performance
-5.52%
Score breakdown
Down 5.5% over 1 year, 46% of the 52-week range.
Strongest: Shareholder return 8.3/10. Weakest: Valuation 5.4/10.
28 analysts, target +0.2% vs the price.
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name.
This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nyse
Ireland
CEO
Mr. Geoffrey Straub Martha
Founded
1949
Employees
95 000
Revenue / employee
382 779 USD
Next earnings
November 24, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
106.33 USD
52-week low
73.31 USD
1-year performance
-5.52%
Declining
Year-to-date performance
-7.02%
Declining
Drawdown
-16.78%
Marked drawdown
Position in the 52-week range
46% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned less, while shaking 1.7 times harder.
10,000 € placed at the end of September 2009 are worth today
| Medtronic | 46 883 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 1.7 times as much as the world ETF.
- Worst fall:-39 % between August 2021 and November 2023. 10,000 € placed at the top fell to 6 113 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Medtronic earned less than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Medtronic: 46 883 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 93.60 USD - 102.49 USD (3 methods agree)
The price implies growth of 4.07% per year; the company grows at 6.95%.
Gross margin 60.6%, net margin 13.9%, ROIC 7.0%, ROE 10.7%.
Net margin
13.94%
Exceptional
Sector 8.18%|S&P 12.97%
Gross margin
60.56%
Fair
Return on equity (ROE)
10.66%
Exceptional
Sector 6.97%|S&P 16.52%
Return on invested capital (ROIC)
6.98%
Fair
Free cash flow margin (FCF)
16.33%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.17x
High
Margin stability
1.9 pts
Very steady
Revenue to net income
Growth
7.1/10Revenue up 13.7% over 1 year, 3.8% a year over 5, EPS 7.0% a year over 5.
Revenue (trailing 12 months)
37.5Md USD
Revenue growth (1y)
13.73%
Hyper-growth
Revenue growth (3y)
16.45%
Solid
EPS growth (1y)
41.57%
Hyper-growth
EPS CAGR (5y)
6.95%
Low
EPS revisions (3 months)
0.44%
Revised up
Valuation
5.4/10P/E 21.8x, forward P/E 18.7x, EV/EBITDA 14.2x, PEG 3.13. The multiple sits in the 25th percentile of its own 5-year history.
P/E (TTM)
21.8x
Fair
Sector 29.3x|S&P 23.0x
Forward P/E
18.7x
Fair
EV / EBITDA
14.2x
Fair
Sector 16.0x|S&P 14.5x
PEG
3.13
Very expensive
Sector 1.76|S&P 0.86
Fair value (reverse DCF)
98.05 USD
Undervalued
P/E vs its own 5-year history
among the 25% lowest valuations
Cheaper than usual
Market cap
114Md USD
Financial strength
7.2/10Cash covers 31.3% of the debt, net debt/EBITDA 2.0x.
Net debt / EBITDA
2.0x
Tight
Gearing (net debt / equity)
38.02%
Solid
Cash
8.8Md USD
Cash / market cap
7.72%
Tight
Cash / total debt
31.33%
Solid
Interest coverage
9.4x
Solid
Net debt
19.3Md USD
Equity
50.9Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 88.51 USD
- MM2091.78
- MM5089.36
- MM20089.03
- RSI 1440.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-0.88%
200-day average slope, 3 months
-2.88%
50-day average slope, 1 month
+5.35%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.27 % per day
Volatility change
-21.15%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 4.73 (8) | 5.97 (26) | 39 062 (23) | 10 927 (11) | 6 039 (10) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 24, 2026.
Same sub-industry: 190 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BSX | 7.0 | 7.2 | 64.7Md USD | 18.1x | 17.5 % | 7.5 % | 10.5 % | 1.8x | 5.6 % | -54.3 % | ||
| 2 | SYK | 6.9 | 7.5 | 105Md USD | 28.3x | 14.4 % | 9.4 % | 10.0 % | 1.7x | 4.5 % | -27.6 % | ||
| 3 | MDT | 6.8 | 6.9 | 114Md USD | 21.8x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 5.4 % | -5.5 % | ||
| 4 | ABT | 6.6 | 6.3 | 179Md USD | 33.5x | 11.6 % | 13.0 % | 7.5 % | 0.5x | 4.4 % | -25.3 % | ||
| 5 | ISRG | 6.5 | 6.8 | 141Md USD | 45.6x | 28.4 % | 18.5 % | 17.4 % | -1.6x | 2.3 % | -11.4 % | ||
| 6 | IDXX | 6.3 | 6.4 | 41.1Md USD | 36.7x | 25.0 % | 9.7 % | 56.6 % | 0.5x | 3.0 % | -20.4 % | ||
| 7 | SHL | 6.3 | 6.5 | 47.2Md USD | 18.9x | 9.6 % | 1.8 % | 7.4 % | 2.7x | 5.4 % | -20.5 % | ||
| 8 | EW | 6.2 | 5.6 | 50.0Md USD | 51.5x | 15.0 % | 13.6 % | 8.7 % | -2.0x | 2.9 % | 15.4 % | ||
| 9 | BDX | 5.7 | 5.1 | 49.7Md USD | 55.1x | 6.2 % | 5.4 % | 3.2 % | 3.4x | 5.1 % | 22.7 % |
